The Swiss pharma company has reached a “tentative agreement” to settle a class-action lawsuit related to the launch of generic versions of its hypertension drug. The deal has yet to be approved by US judges.
This content was published on
2 minutes
Keystone-SDA/dos
Español
es
Novartis concluye acuerdo extrajudicial en Estados Unidos
The Basel-based multinational told the AWP news agency on Thursday it had agreed to pay $245 million (CHF227 million) to three groups of plaintiffs to fully settle the case.
The antitrust litigation stemmed from a 2011 patent agreement between Novartis and Par, a pharmaceutical subsidiary of US-based Endo International. The two companies were accused of illegally colluding to delay the launch of cheaper generic versions of Novartis’ Exforge, a treatment designed to lower blood pressure and reduce the risk of strokes.
The plaintiffs accused Par of agreeing not to launch an Exforge generic for two years after a patent expired, and Novartis of agreeing not to compete with Par by launching its own generic for 180 days after Par entered the market.
More
More
What’s behind the Novartis job cuts?
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure – it’s a turning point for Novartis.
In its statement, Novartis said the three groups which filed the lawsuit were direct purchasers, indirect purchasers and resellers. The out-of-court settlement, which has yet to be cleared by US judges, “will resolve all outstanding claims related to this matter for Novartis”, the company said.
According to court documents cited by Reuters, annual sales of Exforge in the US were over $400 million before the generic versions were marketed. Reuters also reports that the plaintiffs include major pharmacy chains such as CVS Health, Rite Aid and Walgreens Boots Alliance.
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
Swiss researchers improve therapy for paralysed patients
This content was published on
Using rehabilitation robots and a spinal cord implant, Swiss researchers are helping people with spinal cord injuries to walk again.
New Swiss government minister prepared for defence mandate
This content was published on
New Swiss government minister Martin Pfister says he is prepared for the defence mandate sif he be asked to take on the vacant role.
Swiss-backed ‘Hera’ asteroid mission hits key milestone with Mars flyby
This content was published on
According to the European Space Agency (ESA), the Red Planet’s gravity will tweak the probe’s path, cutting months off the journey and saving a lot of fuel.
Swiss man arrested over Geneva parcel bomb attacks
This content was published on
A 61-year-old Swiss man was arrested in Geneva in connection with the parcel bomb incidents that left a man and a 12-year-old girl seriously injured.
UN officials in Geneva report over 100 civilian executions in western Syria
This content was published on
Verification is ongoing, and the actual number is likely higher, said a UN spokesperson in Geneva. A Syrian NGO claims executions could exceed 1,000.
Swiss pharma giant Roche partners with Zealand Pharma on new obesity treatment
This content was published on
Roche announced that it has struck an exclusive deal with Denmark's Zealand Pharma to develop and market petrelintide, a new treatment for obesity.
Experts lower Swiss growth forecasts due to US trade tensions
This content was published on
The uncertainty caused by ongoing trade conflicts is making companies hesitant to make decisions, which significantly hinders investment.
Swiss abbot resumes role following abuse investigation
This content was published on
Scarcella was accused in the Catholic Church abuse scandal last autumn. In October 2024, the Vatican declared there was no evidence of abuse or harassment against him.
Swiss stock exchange operator SIX to cut 150 jobs in efficiency drive
This content was published on
"We're not revealing the number of job losses at each location at the moment," said a SIX spokesperson. However, there will be cuts in Switzerland as well.
Martin Pfister named new Swiss government minister
This content was published on
Pfister’s election keeps the linguistic balance of Switzerland’s government, but shifts gender balance to only two women.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Competition authorities probe Novartis over suspected patent abuse
This content was published on
The Swiss competition commission (COMCO) has opened an investigation into suspected unlawful use of a patent by Novartis.
Novartis sets sights on high-value medicines and US market
This content was published on
Swiss pharma giant Novartis has unveiled an updated strategy focused on high-value medicines and boosting its position in the US market.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.